Chemotherapy remains the mainstay of treatment for advanced breast cancer, however, resistance is an inevitable event for the majority of patients with metastatic disease.
Introduction
Despite significant advances in the systemic treatment of breast cancer, metastatic disease is still considered incurable with the 5-year survival rate at 25% (www.seer.cancer.gov). Thus, the acquisition of resistance is often an inevitable event in advanced disease. As a consequence, there is an urgent need to not only develop new therapeutics, but also identify clinically relevant mechanisms of resistance and predictive biomarkers of response for the mainstay treatment for advanced disease, namely chemotherapeutic reagents (1) . Chemotherapy selection has traditionally been guided by large randomized trials based only on the origin of disease (2) , as opposed to molecularly defined disease subtypes. In addition, with the plethora of clinically approved chemotherapeutics, there is a lack of information to guide personalization of chemotherapeutic approaches and stratify patients on the basis of predicted response (3) .
Loss of function genetic screening, particularly the exploitation of RNA interference (RNAi), has emerged as a high throughput and unbiased approach to identify genes associated with a phenotype of interest (4) . In vitro RNAi screens have been fundamental to the understanding of mechanism of action of molecularly targeted therapeutics and their resistance pathways (5) . However, such screens are unable to differentiate the mechanisms of greatest clinical relevance, and may miss additional in vivo specific drivers of response and resistance (6, 7) . In vivo RNAi screening has emerged as a physiologically relevant approach to explore gene function in tumor biology (8) (9) (10) and therapeutic response (11) . In this study, we have adapted an in vivo short hairpin (sh)RNAi approach combined with massively parallel sequencing to reveal novel determinants of response to anthracycline chemotherapy in a model of breast cancer metastasis.
Using this approach, we identified c-Jun N-terminal kinase 1 (JNK1) as a clinically relevant determinant of sensitivity to anthracycline chemotherapy. The JNK family of mitogen activated protein kinases (MAPKs) has been implicated in the pathogenesis of a number of tumor types, plus in other pathologies such as autoimmune disease (12, 13) . However, multiple roles have been proposed for these kinases, on one hand preventing malignant
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transformation via induction of apoptosis, on the other promoting cell survival in established tumors. Our study supports a dual role for the JNK family in advanced breast cancer, identifies the potential of monitoring JNK activity as an early biomarker of response and has implications when considering therapeutic strategies that combine cytotoxic chemotherapy with agents that promote a cytostatic response. S1A ) and mice were treated with AC chemotherapy (2.5 mg/kg doxorubicin, 40 mg/kg of cyclophosphamide) or vehicle on days 2, 7, 11 and 16. On day 21, tumor burden was assessed by in vivo IVIS imaging and ex vivo lung weight, and gDNA was extracted from pre-inoculation cell pellets and tumor bearing lungs (10) . Supplementary Fig. S1B outlines the strategy for combining samples prior to PCR amplification and high-throughput sequencing (15) . Raw image data were analyzed using GA pipeline v1.8 and short reads
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aligned to the shRNA library sequences using shALIGN (15) and subject to quality control testing ( Supplementary Fig. S1C ).
Human datasets
The procedure to generate JNK activity signature (JAS) and proliferation independent JAS (piJAS) scores based on the H-JNK versus L-JNK gene set of Chang et al. (16) is described fully in Supplementary Fig. S2 .
piJAS and JAS scores were assessed for breast cancer samples in TCGA (17) METABRIC (18) In all cases; *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant. S3 ) and tolerable over the 21 day assay (Fig. 1A) . Moreover, the high dose AC combination, compared to the low dose combination, led to a significant reduction in tumor burden (Fig. 1B) . The high dose AC combination was used in all further studies.
Results
An
For the in vivo screen, we employed the Cancer 1000 shRNA library consisting of 2204 shRNAs, targeting a panel of ~1000 cancer-associated mouse genes (8, 23) , with a subpool complexity of 96 shRNAs (24 subpools). The screen strategy is outlined in Fig. 1C . From this shortlist, the potential interaction between Mapk8 (Jnk1) and the transcription factor Elk3 (ETS domain-containing protein 3) was of interest given reports that activated JNK phosphorylates the ETS family member ELK1 (25, 26) . Further, the observation that independent shRNAs targeting Mapk8 were enriched in tumors isolated from AC-treated, compared to vehicle-treated, mice implicated a contribution of JNK signaling to tumor cell chemotherapeutic killing in vivo.
Inhibition of JNK signaling impairs pro-apoptotic signaling and promotes resistance to anthracyclines in mouse and human models of breast cancer
To validate the effects of inhibiting JNK activity in vivo, 4T1-Luc cells were transduced with two independent shRNAs targeting Mapk8 (Jnk1) (shMapk8-1; shMapk8-2) that were distinct from the shRNAs in the Cancer 1000 library ( Fig. 2A) . As the JNK family contains two other members that are targets for pan-JNK inhibitors, cells were also transduced with two independent shRNAs targeting Mapk9 (Jnk2) (shMapk9-1; shMapk9-2) ( Fig. 2A) . Mapk10 (Fig. 3A) . In combination with doxorubicin treatment, SP600125 resulted in a dose dependent reduction in doxorubicin-mediated cell killing (Fig.   3B ). However, SP600125 alone at higher concentrations impaired the proliferation of 4T1-Luc cells (Fig. 3C) . Therefore, to quantify the level of SP600125 antagonism, the observed inhibition of the combined agents was compared to the expected inhibition based on the single agent response curves. Using a Bliss additive model (31) , which is appropriate where the two agents are not directed against the same target, antagonism was observed across the SP600125 and doxorubicin drug concentrations (Fig. 3D ). More strikingly, in a colony formation assay (Fig. 3E ), SP600125 treatment alone had little effect but was able to effectively rescue the doxorubicin-mediated severe reduction in colony number. Of note, although SP600125 alone did not impair colony number, colony size was reduced consistent with a cytostatic effect of JNK inhibition.
As proliferation rate is known to be associated with chemotherapy response (32), it was critical to confirm that the resistance mediated by JNK knockdown or inhibition was independent of its cytostatic effect. Compared to the effects observed in subconfluent cells (Fig. 3B ) and on the colony size in the colony formation assay (Fig. 3E) , SP600125 treatment alone, at two different concentrations, had no significant impact on cell viability in confluent cultures ( Fig. 3F ; Supplementary Fig. 5A ), supporting the concept that the JNK inhibition results in cytostasis rather than cytotoxicity. In contrast, in these confluent cultures doxorubicin retained its ability to significantly impair cell viability and this effect was significantly abrogated by SP600125 in the combination treatment. Equivalent results were obtained using the higher specificity inhibitors, JNK inhibitor VIII and JNK-IN-8. Similarly, in confluent cultures, treatment with the three JNK inhibitors alone did not promote apoptosis whereas the number of apoptotic cells was substantially increased following doxorubicin treatment (Fig. 4A) . Again, all three JNK inhibitors significantly abrogated doxorubicininduced cell apoptosis.
As further support for JNK modulating doxorubicin resistance independent of its cytostatic effect, we examined downstream apoptotic effectors. JNK inhibition had no effect on the total levels of Bax or cleavage of caspase 3. Conversely, doxorubicin treatment enhanced c-Jun phosphorylation and substantially increased the level of cleaved caspase-3, effects that were effectively rescued by all three JNK inhibitors (Fig. 4B) . Phosphorylation of the pro-apoptotic Bcl-2 family member Bax results in activation and translocation to the mitochondrial membrane, and an antibody specific for the active confirmation of Bax (33) only stains caspase 3 positive cells ( Supplementary Fig. S5B ). JNK inhibition alone did not promote Bax activation but, at two different concentrations, all three JNK inhibitors significantly abrogated doxorubicin-induced Bax-activation ( Fig. 4C; Supplementary Fig. 5C ).
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Equivalent results were obtained with human MDA-MB-231 cells (Fig. 5A ). In conclusion, In hepatocellular carcinoma, and a gene expression signature of JNK activity has been associated with poor overall survival (16). However, this signature contains a number of proliferation-associated genes that could confound potential differences in patient prognosis, an issue of particular importance in breast cancer where a high proliferation index is associated with poor prognosis (36, 37) . Consequently, proliferation associated genes were removed from the JNK activity signature (JAS) as described in Supplementary Fig. S2 to generate a proliferation-independent JAS (piJAS). Using this piJAS, proliferationindependent JNK activity scores were generated for samples classified by receptor status ( Fig. 6A,B ; Supplementary Table S6) Fig. S6G ).
Increased JNK activity predicts response to neoadjuvant chemotherapy in human breast cancer To address whether JNK activity had prognostic value in determining response to chemotherapy in human breast cancers, we focused on the TN tumors given that JNK activity was highest in these cancers. Importantly, the TN breast cancers are most likely to be treated with chemotherapy, given a lack of targeted therapeutics. Further, despite having greater chemotherapy response rates, TN breast cancer patients have the highest relapse and poorest survival rates (21, 38) , with the majority of events occurring within the first 60 months post diagnosis (39, 40) . In TN breast cancers that were not treated with chemotherapy ( Fig. 6C ; see Supplementary Table S7 for clinical details), high JNK signaling, as monitored by a high piJAS score, showed a significant correlation with a poorer patient outcome (breast cancer specific deaths), indicating that a high JNK activity is associated with a more aggressive tumor phenotype. Conversely, in the chemotherapy treated patients, JNK signaling had no prognostic value (Fig. 6D ), indicating that, despite conferring a more aggressive phenotype, high JNK activity is also associated with an increased response to chemotherapy.
On the basis of these findings, we turned to JNK activity as a predictor of chemotherapy response in randomized neoadjuvant trials. The study of de Ronde and colleagues (19) contains gene expression profiling from 178 biopsies of HER2-negative breast cancers taken prior to neoadjuvant anthracycline chemotherapy. Again, highest piJAS scores were found in the TN and basal-like breast cancers ( Supplementary Fig. S7A ,B;
Supplementary Table S6) . Critically, the piJAS score was significantly higher in pathological Table S6) . Again, a significantly higher piJAS score was detected in the pCR group compared to those with residual disease, whether assessing all patients (pCR in 34/133; Fig. 6G ) or only TN patients (pCR in 13/27; Fig. 6H ).
Discussion
In vitro RNAi screens have been critical for understanding mechanisms of resistance to molecularly targeted agents in cancer (5,7), however, such approaches have not been informative in studying resistance to cytotoxic chemotherapy (7), which remains a mainstay of treatment for metastatic disease. The study design models the use of adjuvant chemotherapy, following surgery, to prevent the establishment of metastatic disease. The goal was to integrate RNAi technology with this model to identify modulators of chemotherapy response in metastatic breast cancer in vivo. We demonstrate the feasibility of this approach and identify the JNK pathway as critical for response to doxorubicin, a prototypical member of the anthracycline chemotherapeutic class.
The JNK pathway is associated with a number of disease states including diabetes, cancer, as well as inflammatory and neurodegenerative disorders (12) . As a result, the JNK family represents an attractive drug target and a number of inhibitors have been developed. Intriguingly the kinases MAP3K1 and MAP2K4, upstream members of the JNK pathway, are the 4th and 7th most frequently mutated genes in breast cancer, respectively (17) , and exhibit a mutually exclusive pattern (49) . The majority of these mutations are predicted to result in loss of function (7, 8) , and are found almost exclusively in luminal disease (17, 49) . In addition, MAP2K4 is frequently associated with loss of heterozygosity events (17, 18) . The absence of these mutations in TN/basal-like breast cancers suggest that signaling via the JNK pathway may be an important driver of proliferation and survival in these subtypes, a concept supported by the demonstration of the differential sensitivity of ER+ and ER-breast cancer cell lines to JNK inhibition (Fig. 5C,D) . Furthermore, the increased JNK activity in ER-disease (Fig. 6A,B) may create a unique vulnerability, and provide an explanation for the higher sensitivity of ER-tumors to chemotherapy (49) .
Using a previously developed signature of JNK pathway activity (16), we confirmed the association of JNK activity with the TN and basal-like breast cancer subtypes in two large breast cancer gene expression datasets (17, 18) . Furthermore, when proliferation genes were removed from the signature, this correlation was maintained confirming the association is not driven by the higher proliferation rate of these subtypes (17) . In the prognostic setting, the proliferation independent signature was associated with poor outcome only when chemotherapy was absent from the treatment regime, further supporting a dual role of the JNK pathway in promoting both tumor aggressiveness (see Fig. 2C ,D) and response to chemotherapy. Critically, in two independent neoadjuvant trials of anthracycline chemotherapy (19, 20) , the proliferation independent signature was predictive of response. 
